STAT+: New results show Cassava’s Alzheimer’s drug has placebo-like efficacy

Cassava Sciences had long claimed that its experimental treatment for Alzheimer’s disease was capable of improving the cognition of patients — a benefit no other Alzheimer’s drug has ever shown.

But mid-stage study results updated on Tuesday now show the cognitive status of patients worsening to the point where Cassava’s drug, called simufilam, doesn’t look any more effective than a placebo.

Continue to STAT+ to read the full story…